<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261546</url>
  </required_header>
  <id_info>
    <org_study_id>Hospital Infanta Sofia</org_study_id>
    <secondary_id>2009-012963-33</secondary_id>
    <nct_id>NCT01261546</nct_id>
  </id_info>
  <brief_title>Clinical Trial Corticoids For Empyema And Pleural Effusion In Children</brief_title>
  <acronym>CORTEEC</acronym>
  <official_title>MULTICENTRIC, PHASE II, CLINICAL TRIAL CORTICOIDS FOR EMPYEMA AND PLEURAL EFFUSION IN CHILDREN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Infanta Sofia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatrics Spanish Association (Madrid and Castilla-La Mancha Pediatric Association)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Ministry of Health.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Infanta Sofia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY JUSTIFICATION&#xD;
&#xD;
        1. Scientific evidence of the usefulness of corticosteroid use for infectious diseases:&#xD;
           Corticosteroids along with antibiotic use improve survival in some infectious processes&#xD;
           provide long term benefits and improve symptoms in many others.&#xD;
&#xD;
        2. Clinical Observation: the investigators observed that patients with parapneumonic&#xD;
           pleural effusion and associated bronchospasm who were treated with corticosteroids for&#xD;
           their bronchospasm, evolved to healing before patients who were not treated with&#xD;
           corticosteroids (average admission days 10 vs. 17).&#xD;
&#xD;
        3. Rationale: the anti-inflammatory effect has been the rationale for the use of&#xD;
           dexamethasone as an inhibitor of the inflammatory response observed after the first dose&#xD;
           of parenteral antibiotic in bacterial meningitis. A similar effect is likely to occur in&#xD;
           pneumonia with pleural effusion. It can be therefore hypothesized that Dexamethasone&#xD;
           could inhibit an excessive inflammatory response by mesothelial and inflammatory cells&#xD;
           during the early phases of parapneumonic empyema, reducing its severity and hence its&#xD;
           complications.&#xD;
&#xD;
      OBJECTIVES&#xD;
&#xD;
        1. Principal: to investigate if dexamethasone 0,25mg/kg q.i.d. added to standard antibiotic&#xD;
           therapy reduces time to resolution of parapneumonic pleural effusion.&#xD;
&#xD;
        2. Secondary:&#xD;
&#xD;
      2.1. Evaluate the effect of dexamethasone 0,25mg/kg q.i.d. added to standard antibiotic&#xD;
      therapy on the development of complications during pleural effusion episode.&#xD;
&#xD;
      2.2. Evaluate the incidence of severe and non severe adverse events associated with the new&#xD;
      treatment versus standard therapy.&#xD;
&#xD;
      METHODS&#xD;
&#xD;
        1. Study design: exploratory (pilot), randomized, double blinded, placebo controlled,&#xD;
           parallel stratified design, multicentric.&#xD;
&#xD;
        2. Participating Hospitals (n=56, 7 patients per center):&#xD;
&#xD;
             -  Hospital Infanta Sofía (S. Sebastián de los Reyes, Madrid).&#xD;
&#xD;
             -  Hospital Universitario de Getafe&#xD;
&#xD;
             -  Hospital Universitario Ramón y Cajal, Madrid.&#xD;
&#xD;
             -  Hospital Universitario Materno-Infantil Carlos Haya, Málaga.&#xD;
&#xD;
             -  Hospital Infantil La Paz, Madrid.&#xD;
&#xD;
             -  Hospital U. Gregorio Marañón&#xD;
&#xD;
             -  Hospital U. Príncipe de Asturias&#xD;
&#xD;
             -  Hospital Virgen de la Salud, Toledo&#xD;
&#xD;
        3. Endpoints:&#xD;
&#xD;
           3.1. Primary: time to resolution. 3.2. Secondary endpoints:&#xD;
&#xD;
             1. Effectiveness: number of children with complications.&#xD;
&#xD;
             2. Safety (expected number: none). i) Hyperglycemia ii) Signs of gastrointestinal&#xD;
                bleeding iii) Need of transfusion iv) Oropharyngeal Candidiasis v) Allergic&#xD;
                reaction vi) Other adverse reactions described in the Medication Guide.&#xD;
&#xD;
        4. Treatment arms:&#xD;
&#xD;
      3.1. Control (0)&#xD;
&#xD;
        -  Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.&#xD;
&#xD;
        -  Cefotaxime 150 mg/kg, IV, q.d. until discharge criteria are present.&#xD;
&#xD;
        -  Ranitidine 5 mg/kg IV, q.d. for 2 days.&#xD;
&#xD;
        -  Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.&#xD;
&#xD;
      3.2. Study treatment: (1)&#xD;
&#xD;
        -  dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.&#xD;
&#xD;
        -  Cefotaxime 150 mg/kg, IV, q.d. until discharge criteria are present&#xD;
&#xD;
        -  Ranitidine 5 mg/kg IV, q.d. for 2 days&#xD;
&#xD;
        -  Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.&#xD;
&#xD;
           4. INCLUSION CRITERIA&#xD;
&#xD;
        -  Patients between 1 and 14 year old.&#xD;
&#xD;
        -  Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever and&#xD;
           radiological consolidation.&#xD;
&#xD;
        -  Evidence of pleural effusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to resolution</measure>
    <time_frame>1 month after admission</time_frame>
    <description>days from diagnosis until criteria for cure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of children with complications.</measure>
    <time_frame>3 months after diagnosis</time_frame>
    <description>number of children with complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children with complications attributable to corticoids</measure>
    <time_frame>3 months</time_frame>
    <description>Hyperglycemia Signs of gastrointestinal bleeding Need of transfusion Oropharyngeal Candidiasis Allergic reaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Parapneumonic Pleural Effusion</condition>
  <condition>Empyema</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.&#xD;
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present&#xD;
Ranitidine 5 mg/kg IV, q.d. for 2 days&#xD;
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.&#xD;
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.&#xD;
Ranitidine 5 mg/kg IV, q.d. for 2 days.&#xD;
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.&#xD;
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present&#xD;
Ranitidine 5 mg/kg IV, q.d. for 2 days&#xD;
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.&#xD;
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.&#xD;
Ranitidine 5 mg/kg IV, q.d. for 2 days.&#xD;
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 1 and 14 year old.&#xD;
&#xD;
          -  Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever&#xD;
             and radiological consolidation.&#xD;
&#xD;
          -  Evidence of pleural effusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to any of the drugs included in the study.&#xD;
&#xD;
          -  Immunodeficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Castilla La Mancha</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Principe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofia</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28037</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pleural effusion, empyema, corticoids, dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empyema</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

